ArticleActa neuropathologica communications2026
Spatial characterisation of TREM2 expression in actively demyelinating multiple sclerosis lesions supports its key roles in lipid metabolic pathways.
Article in Acta neuropathologica communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microglial handling of myelin debris and remyelination after ischaemic stroke: recognition, intracellular processing, lipid fate, and oligodendroglial repair.Frontiers in cellular neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Reactive macrophages and microglia are predominant myeloid cell types in demyelinating multiple sclerosis (MS) lesions in the central nervous system (CNS). Triggering receptor expressed on myeloid cells-2 (TREM2) promotes clearance of myelin debris, supporting remyelination in preclinical models. However, the relevance of TREM2 in people with MS is less understood. We evaluated TREM2 expression and function in autopsy CNS tissues from individuals with and without MS. Spatial transcriptomics and gene co-expression network analysis revealed TREM2 expression in chronic active MS lesioned white matter, where it was localised to glial cell rich clusters associated with lipid and cholesterol metabolism, cellular heat acclimation pathways, and regulation of oligodendrocyte precursor migration and differentiation. Immunofluorescence analysis confirmed that TREM2 was highly expressed in actively demyelinating MS white matter lesions (active lesion centres and chronic active lesion rims). In these areas, TREM2 was found in reactive microglia, perivascular macrophages, and infiltrating parenchymal macrophages. Similarities were observed between perilesional white matter (PLWM) and chronic active lesion rims, including presence of TREM2+ reactive microglia, which were rare in normal appearing white matter (NAWM). TREM2+ cells co-expressed microglia/macrophage markers Iba1, MHC class II, MS4A4A, CD68 and/or CD163, and PLIN2, a lipid storage marker. Almost all TREM2+ cells in active demyelinating white matter were also PLIN2+, while these cells were absent in NAWM. Abluminal TREM2+ PLIN2+ CD163+ vessel macrophages were particularly prominent in actively demyelinating MS white matter where they may play important roles in lipid metabolism and storage in the context of active demyelination. These findings highlight the involvement of TREM2 on both resident and infiltrating myeloid cell populations in response to the demyelinating insult within MS lesions that may directly or indirectly impact local oligodendrocyte myelination capacity and neuroprotection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.